Cervical Pessary Does Not Reduce the Rate of Preterm Births or Neonatal Complications in Twin Gestations

Large international study in the American Journal of Obstetrics & Gynecology shows that this intervention is not effective

Philadelphia, PA, Aug 27, 2015

Having twins accounts for only 1.5% of all births but 25% of preterm births, the leading cause of infant mortality worldwide. Successful strategies for reducing singleton preterm births include prophylactic use of progesterone and cervical cerclage in patients with a prior history of preterm birth. To investigate whether the use of a cervical pessary might reduce premature births of twins, an international team of researchers conducted a large, multicenter, international randomized clinical trial (RCT) of approximately 1200 twin pregnancies. They report in the American Journal of Obstetrics & Gynecology that placement of a cervical pessary did not reduce spontaneous preterm births or reduce neonatal complications.

The rates of preterm birth (defined as <37, <34, or <32 weeks) are 5-6 times higher in twin than in singleton gestations. A cervical pessary is a plastic device that can be placed around the cervix in order to keep it closed and “long” in the hope that it will prevent preterm delivery.

“Twin pregnancies are at substantially higher risk of early preterm birth than singleton pregnancies and this risk is inversely related to sonographically measured cervical length at 20-24 weeks’ gestation,” explained lead investigator Kypros H Nicolaides, MD, Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London. “Our research indicates that insertion of cervical pessary at around 22 weeks in both randomly selected women pregnant with twins and in patients with a short cervix of less than 25 millimeters does not reduce the rate of spontaneous early preterm birth, perinatal death, adverse neonatal outcome, or need for neonatal therapy.”

1180 women pregnant with twins participated in this multicenter RTC (centers in Europe, Asia, and South America), one of the largest studies ever conducted in twin gestations. 590 patients received cervical pessaries while 590 had expectant management. There were no significant differences between the pessary and control group in rates of spontaneous birth at less than 34 weeks (13.6% vs. 12.9%), perinatal death (2.5% vs. 2.7%), adverse neonatal outcome (10.0% vs. 9.2%), or neonatal therapy (17.9% vs. 17.2%).

Two RCTs published after the start of this study provided  contradictory results on the effect of cervical pessary on the rate of spontaneous birth at <34 weeks in singleton pregnancies with short cervix. Dr. Nicolaides and co-investigators conducted a post hoc subgroup analysis of 214 women with short cervix (<25 mm), which also showed no benefit from the insertion of a cervical pessary.

“This is a major international study examining an important clinical question – namely, whether a cervical pessary can reduce the rate of preterm delivery in twin gestations,” commented Roberto Romero, MD, DMedSci, Editor-in-Chief for Obstetrics of the American Journal of Obstetrics and Gynecology, and Chief of the Perinatology Research Branch of NICHD/NIH. "Importantly, a cervical pessary did not reduce the rate of preterm delivery in women with either a short or long cervix. The report is key because many had hope that placement of this doughnut-like device would prevent preterm delivery. The results can be used to focus research on other therapeutic interventions that may be more effective in preventing preterm delivery in twin gestations."

---

Notes for editors
“Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial,” by Kypros H. Nicolaides, MD, Argyro Syngelaki, RM, Liona C. Poon, MD, Catalina de Paco Matallana, MD, Walter Plasencia, MD, Francisca S. Molina, MD, Gemma Picciarelli, MD, Natasa Tul, MD, Ebru Celic, MD, Tze Kin Lau, MD, Roberto Conturso, MD. (DOI: http://dx.doi.org/10.1016/j.ajog.2015.08.051), Published online in advance of its issue of the American Journal of Obstetrics & Gynecology, by Elsevier.

Full text of this article is openly available at www.ajog.org/article/S0002-9378(15)00933-3/abstract. Contact Eileen Leahy at +1 732 238 3628 or ajogmedia@elsevier.com for additional information. Journalists wishing to interview the authors should contact Dr. Kypros H. Nicolaides at Kypros@fetalmedicine.com. Dr. Roberto Romero may be reached for comment at rr.ajoged@gmail.com.

About the American Journal of Obstetrics & Gynecology 
The American Journal of Obstetrics & Gynecology (www.AJOG.org), known as “The Gray Journal,” presents coverage of the entire spectrum of the field, from the newest diagnostic procedures to leading-edge research. The Journal provides comprehensive coverage of the specialty, including maternal-fetal medicine, reproductive endocrinology/infertility, and gynecologic oncology. It also publishes the annual meeting papers of several of its eight sponsoring societies, including the Society for Maternal-Fetal Medicine and the Society of Gynecologic Surgeons.

The American Journal of Obstetrics & Gynecology's 2014 Impact Factor is 4.704. The journal ranks third in Eigenfactor score, continues to be first in total citations, and is the number 3 journal in the Obstetrics & Gynecology category according to the 2014 Journal Citation Reports®, published by Thomson Reuters, 2015. The journal has also been recognized as one of the 100 most influential journals in Biology & Medicine over the last 100 years, as determined by the BioMedical & Life Sciences Division of the Special Libraries Association (2009).

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Media contact
Eileen Leahy
Elsevier
+1 732 238 3628
ajogmedia@elsevier.com